ABT Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 15.71% compared to Abbott Laboratories's net margin of 12.68%. Abbott Laboratories's return on equity of 12.91% beat Boston Scientific Corp.'s return on equity of 12.55%.

Abbott Laboratories has a consensus price target of $132.28, signalling upside risk potential of 28.59%. On the other hand Boston Scientific Corp. has an analysts' consensus of $100.81 which suggests that it could grow by 60.48%. Given that Boston Scientific Corp. has higher upside potential than Abbott Laboratories, analysts believe Boston Scientific Corp. is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.787, which suggesting that the stock is 21.251% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.926%.

Abbott Laboratories has a quarterly dividend of $0.63 per share corresponding to a yield of 2.32%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 64.54% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.5B, which are larger than Boston Scientific Corp. quarterly revenues of $5.3B. Abbott Laboratories's net income of $1.8B is higher than Boston Scientific Corp.'s net income of $670M. Notably, Abbott Laboratories's price-to-earnings ratio is 27.68x while Boston Scientific Corp.'s PE ratio is 32.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.06x versus 4.74x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 15.71% compared to Abbott Laboratories's net margin of 27.89%. Abbott Laboratories's return on equity of 12.91% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Abbott Laboratories has a consensus price target of $132.28, signalling upside risk potential of 28.59%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $605.08 which suggests that it could grow by 33.85%. Given that Intuitive Surgical, Inc. has higher upside potential than Abbott Laboratories, analysts believe Intuitive Surgical, Inc. is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.787, which suggesting that the stock is 21.251% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.677, suggesting its more volatile than the S&P 500 by 67.7%.

Abbott Laboratories has a quarterly dividend of $0.63 per share corresponding to a yield of 2.32%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 64.54% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.5B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Abbott Laboratories's net income of $1.8B is higher than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Abbott Laboratories's price-to-earnings ratio is 27.68x while Intuitive Surgical, Inc.'s PE ratio is 55.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.06x versus 15.86x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 15.71% compared to Abbott Laboratories's net margin of 12.96%. Abbott Laboratories's return on equity of 12.91% beat Insulet Corp.'s return on equity of 17.89%.

Abbott Laboratories has a consensus price target of $132.28, signalling upside risk potential of 28.59%. On the other hand Insulet Corp. has an analysts' consensus of $351.43 which suggests that it could grow by 72.01%. Given that Insulet Corp. has higher upside potential than Abbott Laboratories, analysts believe Insulet Corp. is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.787, which suggesting that the stock is 21.251% less volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.012%.

Abbott Laboratories has a quarterly dividend of $0.63 per share corresponding to a yield of 2.32%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 64.54% of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.5B, which are larger than Insulet Corp. quarterly revenues of $783.8M. Abbott Laboratories's net income of $1.8B is higher than Insulet Corp.'s net income of $101.6M. Notably, Abbott Laboratories's price-to-earnings ratio is 27.68x while Insulet Corp.'s PE ratio is 57.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.06x versus 5.33x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of 15.71% compared to Abbott Laboratories's net margin of 27.59%. Abbott Laboratories's return on equity of 12.91% beat ResMed, Inc.'s return on equity of 25.44%.

Abbott Laboratories has a consensus price target of $132.28, signalling upside risk potential of 28.59%. On the other hand ResMed, Inc. has an analysts' consensus of $296.87 which suggests that it could grow by 32.48%. Given that ResMed, Inc. has higher upside potential than Abbott Laboratories, analysts believe ResMed, Inc. is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.787, which suggesting that the stock is 21.251% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.928, suggesting its less volatile than the S&P 500 by 7.224%.

Abbott Laboratories has a quarterly dividend of $0.63 per share corresponding to a yield of 2.32%. ResMed, Inc. offers a yield of 1.03% to investors and pays a quarterly dividend of $0.60 per share. Abbott Laboratories pays 64.54% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.5B, which are larger than ResMed, Inc. quarterly revenues of $1.4B. Abbott Laboratories's net income of $1.8B is higher than ResMed, Inc.'s net income of $392.6M. Notably, Abbott Laboratories's price-to-earnings ratio is 27.68x while ResMed, Inc.'s PE ratio is 22.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.06x versus 6.13x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.